Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | M. M. Gounder, T. Michael Bauer, G. K. Schwartz, T.Masters, R. D. Carvajal, S. Song, P. Kumar, R. Gajee, O. Zernovak, M. M. Rosen, J. Peter Kochan, S. Chen, D. Michael Hyman, S. Gokmen, F. Meric-Bern, P. LoRusso, N. Somaiah, A. M. Weise, D. S. Song | ||||||||||||
Title | A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas. | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/166204-176 | ||||||||||||
Abstract Text | J Clin Oncol 34, 2016 (suppl; abstr 2581) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 amp | neuroendocrine tumor | predicted - sensitive | Milademetan | Case Reports/Case Series | Actionable | In a Phase I trial, Milademetan demonstrated safety and preliminary activity in patients with advanced solid tumors, and resulted in prolonged stable disease in 2 patients with MDM2-amplified tumors, 1 with liposarcoma and 1 with carcinoid tumor (J Clin Oncol 34, 2016 (suppl; abstr 2581; NCT01877382). | detail... |